- Home
- GCBC vs YMAB Comparison
GCBC vs YMAB Comparison
Compare GCBC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCBC
- YMAB
- Stock Information
- Founded
- GCBC 1889
- YMAB 2015
- Country
- GCBC United States
- YMAB United States
- Employees
- GCBC N/A
- YMAB N/A
- Industry
- GCBC Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GCBC Finance
- YMAB Health Care
- Exchange
- GCBC Nasdaq
- YMAB Nasdaq
- Market Cap
- GCBC 572.1M
- YMAB 631.1M
- IPO Year
- GCBC 1998
- YMAB 2018
- Fundamental
- Price
- GCBC $30.87
- YMAB $10.10
- Analyst Decision
- GCBC
- YMAB Strong Buy
- Analyst Count
- GCBC 0
- YMAB 9
- Target Price
- GCBC N/A
- YMAB $21.56
- AVG Volume (30 Days)
- GCBC 16.7K
- YMAB 274.1K
- Earning Date
- GCBC 10-22-2024
- YMAB 11-08-2024
- Dividend Yield
- GCBC 1.13%
- YMAB N/A
- EPS Growth
- GCBC N/A
- YMAB N/A
- EPS
- GCBC 1.44
- YMAB N/A
- Revenue
- GCBC $64,078,999.00
- YMAB $84,553,000.00
- Revenue This Year
- GCBC N/A
- YMAB $10.24
- Revenue Next Year
- GCBC N/A
- YMAB $20.21
- P/E Ratio
- GCBC $21.68
- YMAB N/A
- Revenue Growth
- GCBC N/A
- YMAB N/A
- 52 Week Low
- GCBC $23.51
- YMAB $5.29
- 52 Week High
- GCBC $37.25
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- GCBC 47.22
- YMAB 21.95
- Support Level
- GCBC $32.96
- YMAB $12.47
- Resistance Level
- GCBC $34.32
- YMAB $11.11
- Average True Range (ATR)
- GCBC 1.41
- YMAB 1.05
- MACD
- GCBC -0.18
- YMAB -0.52
- Stochastic Oscillator
- GCBC 42.91
- YMAB 4.04
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.